Cargando…
Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines
BACKGROUND: Patient-derived bulk expression profiles of cancers can provide insight into the transcriptional changes that underlie reprogrammed metabolism in cancer. These profiles represent the average expression pattern of all heterogeneous tumor and non-tumor cells present in biopsies of tumor le...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474886/ https://www.ncbi.nlm.nih.gov/pubmed/34565468 http://dx.doi.org/10.1186/s40170-021-00272-7 |
_version_ | 1784575321080594432 |
---|---|
author | Leeuwenburgh, V. C. Urzúa-Traslaviña, C. G. Bhattacharya, A. Walvoort, M. T. C. Jalving, M. de Jong, S. Fehrmann, R. S. N. |
author_facet | Leeuwenburgh, V. C. Urzúa-Traslaviña, C. G. Bhattacharya, A. Walvoort, M. T. C. Jalving, M. de Jong, S. Fehrmann, R. S. N. |
author_sort | Leeuwenburgh, V. C. |
collection | PubMed |
description | BACKGROUND: Patient-derived bulk expression profiles of cancers can provide insight into the transcriptional changes that underlie reprogrammed metabolism in cancer. These profiles represent the average expression pattern of all heterogeneous tumor and non-tumor cells present in biopsies of tumor lesions. Hence, subtle transcriptional footprints of metabolic processes can be concealed by other biological processes and experimental artifacts. However, consensus independent component analyses (c-ICA) can capture statistically independent transcriptional footprints of both subtle and more pronounced metabolic processes. METHODS: We performed c-ICA with 34,494 bulk expression profiles of patient-derived tumor biopsies, non-cancer tissues, and cell lines. Gene set enrichment analysis with 608 gene sets that describe metabolic processes was performed to identify the transcriptional components enriched for metabolic processes (mTCs). The activity of these mTCs was determined in all samples to create a metabolic transcriptional landscape. RESULTS: A set of 555 mTCs was identified of which many were robust across different datasets, platforms, and patient-derived tissues and cell lines. We demonstrate how the metabolic transcriptional landscape defined by the activity of these mTCs in samples can be used to explore the associations between the metabolic transcriptome and drug sensitivities, patient outcomes, and the composition of the immune tumor microenvironment. CONCLUSIONS: To facilitate the use of our transcriptional metabolic landscape, we have provided access to all data via a web portal (www.themetaboliclandscapeofcancer.com). We believe this resource will contribute to the formulation of new hypotheses on how to metabolically engage the tumor or its (immune) microenvironment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40170-021-00272-7. |
format | Online Article Text |
id | pubmed-8474886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84748862021-09-28 Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines Leeuwenburgh, V. C. Urzúa-Traslaviña, C. G. Bhattacharya, A. Walvoort, M. T. C. Jalving, M. de Jong, S. Fehrmann, R. S. N. Cancer Metab Research BACKGROUND: Patient-derived bulk expression profiles of cancers can provide insight into the transcriptional changes that underlie reprogrammed metabolism in cancer. These profiles represent the average expression pattern of all heterogeneous tumor and non-tumor cells present in biopsies of tumor lesions. Hence, subtle transcriptional footprints of metabolic processes can be concealed by other biological processes and experimental artifacts. However, consensus independent component analyses (c-ICA) can capture statistically independent transcriptional footprints of both subtle and more pronounced metabolic processes. METHODS: We performed c-ICA with 34,494 bulk expression profiles of patient-derived tumor biopsies, non-cancer tissues, and cell lines. Gene set enrichment analysis with 608 gene sets that describe metabolic processes was performed to identify the transcriptional components enriched for metabolic processes (mTCs). The activity of these mTCs was determined in all samples to create a metabolic transcriptional landscape. RESULTS: A set of 555 mTCs was identified of which many were robust across different datasets, platforms, and patient-derived tissues and cell lines. We demonstrate how the metabolic transcriptional landscape defined by the activity of these mTCs in samples can be used to explore the associations between the metabolic transcriptome and drug sensitivities, patient outcomes, and the composition of the immune tumor microenvironment. CONCLUSIONS: To facilitate the use of our transcriptional metabolic landscape, we have provided access to all data via a web portal (www.themetaboliclandscapeofcancer.com). We believe this resource will contribute to the formulation of new hypotheses on how to metabolically engage the tumor or its (immune) microenvironment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40170-021-00272-7. BioMed Central 2021-09-26 /pmc/articles/PMC8474886/ /pubmed/34565468 http://dx.doi.org/10.1186/s40170-021-00272-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Leeuwenburgh, V. C. Urzúa-Traslaviña, C. G. Bhattacharya, A. Walvoort, M. T. C. Jalving, M. de Jong, S. Fehrmann, R. S. N. Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines |
title | Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines |
title_full | Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines |
title_fullStr | Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines |
title_full_unstemmed | Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines |
title_short | Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines |
title_sort | robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474886/ https://www.ncbi.nlm.nih.gov/pubmed/34565468 http://dx.doi.org/10.1186/s40170-021-00272-7 |
work_keys_str_mv | AT leeuwenburghvc robustmetabolictranscriptionalcomponentsin34494patientderivedcancerrelatedsamplesandcelllines AT urzuatraslavinacg robustmetabolictranscriptionalcomponentsin34494patientderivedcancerrelatedsamplesandcelllines AT bhattacharyaa robustmetabolictranscriptionalcomponentsin34494patientderivedcancerrelatedsamplesandcelllines AT walvoortmtc robustmetabolictranscriptionalcomponentsin34494patientderivedcancerrelatedsamplesandcelllines AT jalvingm robustmetabolictranscriptionalcomponentsin34494patientderivedcancerrelatedsamplesandcelllines AT dejongs robustmetabolictranscriptionalcomponentsin34494patientderivedcancerrelatedsamplesandcelllines AT fehrmannrsn robustmetabolictranscriptionalcomponentsin34494patientderivedcancerrelatedsamplesandcelllines |